AREXVY’s Expanded Indication Approval

The Therapeutic Goods Administration (TGA) has approved an expanded indication for AREXVY, now including adults aged 50-59 who are at increased risk of respiratory syncytial virus (RSV) disease.

The official indication now reads as follows:

AREXVY is indicated for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in:

  • Adults aged 60 years and older.
  • Adults aged 50 through 59 years who are at increased risk for RSV disease.
Share AREXVY’s Expanded Indication Approval on Facebook Share AREXVY’s Expanded Indication Approval on X (formerly Twitter) Share AREXVY’s Expanded Indication Approval on Linkedin Email AREXVY’s Expanded Indication Approval link